|1.||Beekwilder, Jeroen P: 2 articles (06/2008 - 01/2006)|
|2.||van den Berg, Rutgeris J: 2 articles (06/2008 - 01/2006)|
|3.||van Kempen, Gertrudis Th H: 2 articles (06/2008 - 01/2006)|
|4.||Ypey, Dirk L: 2 articles (06/2008 - 01/2006)|
|5.||O'Leary, M E: 2 articles (09/2005 - 02/2003)|
|6.||Ypey, D L: 2 articles (09/2005 - 02/2003)|
|7.||Chahine, Mohamed: 1 article (03/2014)|
|8.||Thériault, Olivier: 1 article (03/2014)|
|9.||de Groat, William C: 1 article (03/2014)|
|10.||O'Leary, Micheal E: 1 article (03/2014)|
10/01/1999 - "In this animal behavioral study, using rats with nerve injury-induced pain, we examined the possible long-term analgesic effects of epidural administration of a suspension of the local anesthetic, butamben. "
01/11/2012 - "Moreover, butamben attenuated acute animal pain behaviors in a TRPA1- or TRPV4-dependent manner. "
02/01/2003 - "Kv1.1 channels of dorsal root ganglion neurons are inhibited by n-butyl-p-aminobenzoate, a promising anesthetic for the treatment of chronic pain."
06/01/2000 - "Butamben (butyl p-aminobenzoate) has been formulated to provide long-acting treatment for chronic pain. "
07/01/1998 - "Nerve blocks with 5% butamben suspension for the treatment of chronic pain syndromes."
07/01/1998 - "When used as described in this report, 5% butamben suspension appears to be effective for treatment of chronic pain of both cancer and noncancer origin and has a low incidence of adverse sequelae."
03/15/2014 - "n-butyl-p-aminobenzoate (BAB), a local anesthetic, is administered epidurally in cancer patients to treat pain that is poorly controlled by other drugs that have a number of adverse effects. "
07/01/1998 - "This report describes the use of 5% butamben suspension for the treatment of chronic pain of cancer and noncancer origin. "
12/01/1991 - "Long-lasting epidural sensory blockade by n-butyl-p-aminobenzoate in the terminally ill intractable cancer pain patient."
06/01/1995 - "Aqueous suspensions of the local anesthetic n-butyl-p-aminobenzoate (BAB), epidurally applied in terminal cancer patients, resulted in a sensory blockade, lasting up to several months. "
10/01/1999 - "In this behavioral study, we investigated the effect of the epidural administration of a 5% butamben suspension on nerve injury-induced allodynia. "
10/01/1999 - "The long-term effect of epidural administration of butamben suspension on nerve injury-induced allodynia in rats."
10/01/1999 - "We conclude that repeated epidural administration of butamben suspension for several days provides long-lasting analgesia in rats with nerve injury-induced allodynia to mechanical stimulation. "
10/01/1999 - "The allodynia to mechanical stimulation induced by partial nerve ligation was significantly attenuated by daily injections, for 5 days, of 10 microL of butamben suspension. "
03/01/2002 - "This study demonstrates a prolonged antinociceptive effect from butamben nerve block to both formalin-induced nociception and heat hyperalgesia, without an effect on gross motor function or histologic morphology. "
|4.||Allergic Contact Dermatitis
02/01/1978 - "Allergic contact dermatitis from butyl aminobenzoate."
|5.||Pancreatic Neoplasms (Pancreatic Cancer)
12/01/2000 - "Comparison of epidural butamben to celiac plexus neurolytic block for the treatment of the pain of pancreatic cancer."
12/01/2000 - "To compare pain relief in metastatic pancreatic cancer patients between neurolytic celiac plexus block (NCPB) and epidural 5% butamben suspension (EBS), a material-based delivery system of a local anesthetic that produces a long-lasting differential nerve block. "
|4.||4-Aminobenzoic Acid (4 Aminobenzoic Acid)
|8.||antineoplaston A10 (A 10)
|9.||tetracaine drug combination butyl aminobenzoate benzocaine
|10.||picric acid (picrate)
|1.||Nerve Block (Nerve Blocks)